Beta 1 integrin signaling mediates pancreatic ductal adenocarcinoma resistance to MEK inhibition

Pancreatic cancer, one of the deadliest human malignancies, has a dismal 5-year survival rate of 9%. KRAS is the most commonly mutated gene in pancreatic cancer, but clinical agents that directly target mutant KRAS are not available. Several effector pathways are activated downstream of oncogenic Kr...

Descripción completa

Detalles Bibliográficos
Autores principales: Brannon, Arthur, Drouillard, Donovan, Steele, Nina, Schoettle, Shadae, Abel, Ethan V., Crawford, Howard C., Pasca di Magliano, Marina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340786/
https://www.ncbi.nlm.nih.gov/pubmed/32636409
http://dx.doi.org/10.1038/s41598-020-67814-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340786/
https://www.ncbi.nlm.nih.gov/pubmed/32636409
http://dx.doi.org/10.1038/s41598-020-67814-9

Ejemplares similares